<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18381">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867605</url>
  </required_header>
  <id_info>
    <org_study_id>16-142</org_study_id>
    <nct_id>NCT02867605</nct_id>
  </id_info>
  <brief_title>Human Pilot Study - HA35 Dietary Supplement for Promoting Intestinal Health</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether oral HA35 supplementation changes the
      normal intestinal bacteria, increases intestinal protection, decrease intestinal
      inflammation and permeability, and to assess any health benefits and confirm the safety
      profile of HA35.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline stool micro biome diversity and phylogenetic distribution at 8 days and 28 days</measure>
    <time_frame>Baseline, Day 8, Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline comprehensive metabolic panel and complete blood count at day 8 and 28</measure>
    <time_frame>Baseline, Day 8, Day 28</time_frame>
    <description>Change in CMP, CBC levels at 8 days and 28 days after baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline indirect calorimetry at 8 days and 28 days</measure>
    <time_frame>Baseline, Day 8, Day 28</time_frame>
    <description>Change in respiratory quotient at 8 days and 28 days after baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline fecal intestinal antimicrobial peptide secretion at 8 days and 28 days</measure>
    <time_frame>Baseline, Day 8, Day 28</time_frame>
    <description>Change in calprotectin, human beta-defensing at 8 days and 28 days after baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline serum indicators of intestinal permeability at 8 days and 28 days</measure>
    <time_frame>Baseline, Day 8, Day 28</time_frame>
    <description>Change in serum HA, Serum LPS, Serum I-FABP at 8 days and 28 days after baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline serum indicators of inflammation and injury at 8 days and 28 days.</measure>
    <time_frame>Baseline, Day 8, Day 28</time_frame>
    <description>Change in high-sensitivity C-Reactive Protein, IL6, and TN alpha at 8 days and 28 days after baseline</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastrointestinal Microbiome</condition>
  <arm_group>
    <arm_group_label>Healthy Controls ages 18-45 with BMI of 19-25 or 30-35</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hyaluranon</intervention_name>
    <arm_group_label>Healthy Controls ages 18-45 with BMI of 19-25 or 30-35</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Twenty healthy adult volunteers, ten with a lean BMI between 19-25 and ten with an obese
        BMI between 30-35, will complete this study. There will be no restriction to gender or
        race. Age limits will be 18-45 years for this pilot study, since ageing may affect
        intestinal immunity, microbiome composition, prevalence of pre-clinical disease
        confounders
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 19-25 (lean), and BMI 30-35 (obese)

          -  Age 18-45 years old

          -  Willingness to take oral supplement and adhere to study requirements

        Exclusion Criteria:

          -  Diabetes

          -  Oral antibiotics within 4 weeks of study initiation

          -  History of cardiac disease, and medications for cardiac disease

          -  Use statins and antihypertensive drugs

          -  Inflammatory bowel disease including irritable bowel syndrome

          -  History of intestinal surgery, excluding hernia repair and appendectomy

          -  Active cancer diagnosis (except skin cancer)

          -  Chronic acid suppression treatment (proton pump inhibitors, histamine H2 receptor
             antagonists)

          -  Immune modulatory treatments (e.g. chronic immunosuppressive medications, chronic
             NSAIDs)

          -  Vegetarian or vegan diet7

          -  Abnormal liver or kidney function as measured by routine serum chemistry testing

          -  Severe anemia or significant white blood cell or platelet abnormalities

          -  No additional blood or blood product donations during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annette M Bellar, BS</last_name>
    <phone>216-636-5247</phone>
    <email>bellara@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Megan Villareal, BS</last_name>
    <phone>216-636-5247</phone>
    <email>villarm@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette M Bellar, BS</last_name>
      <phone>216-636-5247</phone>
      <email>bellara@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Carol de la Motte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hill DR, Kessler SP, Rho HK, Cowman MK, de la Motte CA. Specific-sized hyaluronan fragments promote expression of human Î²-defensin 2 in intestinal epithelium. J Biol Chem. 2012 Aug 31;287(36):30610-24. doi: 10.1074/jbc.M112.356238. Epub 2012 Jul 3.</citation>
    <PMID>22761444</PMID>
  </reference>
  <reference>
    <citation>Hill DR, Rho HK, Kessler SP, Amin R, Homer CR, McDonald C, Cowman MK, de la Motte CA. Human milk hyaluronan enhances innate defense of the intestinal epithelium. J Biol Chem. 2013 Oct 4;288(40):29090-104. doi: 10.1074/jbc.M113.468629. Epub 2013 Aug 15.</citation>
    <PMID>23950179</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 11, 2016</lastchanged_date>
  <firstreceived_date>August 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Carol De La Motte</investigator_full_name>
    <investigator_title>Assoiciate Staff</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
